APAC Healthcare Weekly (Sept 27) – Hansoh Pharma, Innocare, Astellas, Otsuka, Telix Pharmaceuticals
Hansoh’s risvutatug rezetecan has been included in NMPA’s Priority Review list. Elevar Therapeutics won FDA approval for Lyrfigtu for bile duct...
89 Views
Zylox Tonbridge (2190 HK): Optimed Acquisition Is a Positive Step Forward Towards Future Growth
Zylox-Tonbridge Medical Technology (2190 HK) acquires 49% stake in Optimed GmbH for EUR 18.4M, boosting international expansion with product...
285 Views
Zylox Tonbridge Medical (2190 HK): No More Interventions Needed, Blockages Cleared for Growth
Zylox-Tonbridge Medical carried forward 2024 momentum, moving into 1H25. New launches and strong market sales capabilities will help drive the...
435 Views
Zylox-Tonbridge Medical Technology (2190.HK) - A Good Alpha-Generating Opportunity for Investors
Zylox's strong fundamentals and growth potential have not been fully reflected in current valuation due to market conditions, making it a...
596 Views
APAC Healthcare Weekly (May 31) – Innovent Biologics, Junshi Bio, Henlius Bio, Olympus, GC Bio
Innovent stuck $10.5B outlicensing deal with Pfizer. Olympus will acquire BioProtect. Eli Lilly is acquiring GC Bio’s US affiliate. Dong-A’s...
159 Views